Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Mirati Therapeutics, Inc. | a13-16915_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 19, 2013
MIRATI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35921 |
|
46-2693615 |
|
(State of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
9363 Towne Centre Drive, Suite 200
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (858) 332-3410
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On July 19, 2013, Mirati Therapeutics, Inc. (the “Company”) announced that it had applied to the Toronto Stock Exchange (the “TSX”) to voluntarily delist from trading its shares of common stock. Effective at market close on July 26, 2013, the Company’s common stock will no longer be traded through the facilities of the TSX. The Company’s shares are currently traded, and will continue to be traded, on the NASDAQ Capital Market under the symbol “MRTX”.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated July 19, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: July 22, 2013 |
MIRATI THERAPEUTICS, INC. | |
|
|
| |
|
|
By: |
/s/ Charles M. Baum, M.D., Ph.D. |
|
|
|
Charles M. Baum, M.D., Ph.D. |
|
|
|
President and Chief Executive Officer |